Should I buy or sell Vaxcyte stock right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Vaxcyte in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" PCVX shares. View PCVX analyst ratings or view top-rated stocks .

What is Vaxcyte's stock price target for 2024?

5 equities research analysts have issued 12 month price targets for Vaxcyte's stock. Their PCVX share price targets range from $58.00 to $70.00. On average, they anticipate the company's share price to reach $64.20 in the next twelve months. This suggests a possible upside of 19.3% from the stock's current price. View analysts price targets for PCVX or view top-rated stocks among Wall Street analysts .

How have PCVX shares performed in 2023?

Vaxcyte's stock was trading at $47.95 on January 1st, 2023. Since then, PCVX stock has increased by 12.2% and is now trading at $53.81. View the best growth stocks for 2023 here .

When is Vaxcyte's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, February 26th 2024. View our PCVX earnings forecast .

How were Vaxcyte's earnings last quarter?

Vaxcyte, Inc. (NASDAQ:PCVX) issued its earnings results on Monday, November, 6th. The company reported ($0.91) EPS for the quarter, missing the consensus estimate of ($0.84) by $0.07.

What ETFs hold Vaxcyte's stock?

ETFs with the largest weight of Vaxcyte (NASDAQ:PCVX) stock in their portfolio include ETFMG Treatments Testing and Advancements ETF (GERM) , ALPS Medical Breakthroughs ETF (SBIO) , Alger 35 ETF (ATFV) , Alger Mid Cap 40 ETF (FRTY) , Invesco Dorsey Wright Healthcare Momentum ETF (PTH) , SPDR S&P Biotech ETF (XBI) , Principal Healthcare Innovators ETF (BTEC) and Fidelity Disruptive Medicine ETF (FMED) .

What other stocks do shareholders of Vaxcyte own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Vaxcyte investors own include NVIDIA (NVDA) , Twilio (TWLO) , Boeing (BA) , Overstock.com (OSTK) , Pure Storage (PSTG) , QUALCOMM (QCOM) , Riot Platforms (RIOT) , American Tower (AMT) , Avid Technology (AVID) and CalAmp (CAMP) .

When did Vaxcyte IPO?

(PCVX) raised $210 million in an initial public offering (IPO) on Friday, June 12th 2020. The company issued 14,000,000 shares at a price of $14.00-$16.00 per share. BofA Securities, Jefferies and Evercore ISI acted as the underwriters for the IPO and Cantor and Needham & Company were co-managers.

Who are Vaxcyte's major shareholders?

Vaxcyte's stock is owned by many different retail and institutional investors. Top institutional investors include FMR LLC (14.79%), Wellington Management Group LLP (4.83%), Fred Alger Management LLC (2.20%), Jennison Associates LLC (1.87%), Braidwell LP (1.70%) and Kynam Capital Management LP (1.37%). Insiders that own company stock include Andrew Guggenhime , Grant Pickering , Group Holdings (Sbs) Advis Tpg, Heath Lukatch , Jane Wright-Mitchell , Jeff Fairman , Jim Wassil , Mikhail Eydelman , Paul Sauer and Robert Lorne Hopfner. View institutional ownership trends .

How do I buy shares of Vaxcyte?

Shares of PCVX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Vaxcyte Stock Price, News & Analysis (NASDAQ:PCVX)

$53.81

+2.04 (+3.94%)

(As of 12/1/2023 ET)

Compare

Today's Range: $50.91
▼
$53.94
50-Day Range: $45.35
▼
$53.81
52-Week Range: $34.11
▼
$54.97

Volume: 599,416 shs
Average Volume: 568,824 shs
Market Capitalization: $5.12 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $64.20

Vaxcyte MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 19.3% Upside
$64.20 Price Target
Short Interest: Bearish
7.64% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: -0.03
Based on 3 Articles This Week
Insider Trading: Selling Shares
$4.56 M Sold Last Quarter
Proj. Earnings Growth: Decreasing
From ($3.31) to ($4.15) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.28 out of 5 stars

Medical Sector

916th out of 951 stocks

Biological Products, Except Diagnostic Industry

158th out of 160 stocks

2.5

Analyst's Opinion

Consensus Rating
Vaxcyte has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $64.20, Vaxcyte has a forecasted upside of 19.3% from its current price of $53.81.
Amount of Analyst Coverage
Vaxcyte has only been the subject of 1 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
7.64% of the outstanding shares of Vaxcyte have been sold short.
Short Interest Ratio / Days to Cover
Vaxcyte has a short interest ratio ("days to cover") of 12.6, which indicates bearish sentiment.
Change versus previous month
Short interest in Vaxcyte has recently decreased by 0.82%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Vaxcyte does not currently pay a dividend.
Dividend Growth
Vaxcyte does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for PCVX.

2.2

News and Social Media Coverage

News Sentiment
Vaxcyte has a news sentiment score of -0.03. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.76 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for Vaxcyte this week, compared to 2 articles on an average week.
Search Interest
1 people have searched for PCVX on MarketBeat in the last 30 days.
MarketBeat Follows
15 people have added Vaxcyte to their MarketBeat watchlist in the last 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Vaxcyte insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,562,345.00 in company stock.
Percentage Held by Insiders
Only 3.60% of the stock of Vaxcyte is held by insiders.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Vaxcyte are expected to decrease in the coming year, from ($3.31) to ($4.15) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Vaxcyte is -16.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Vaxcyte is -16.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Vaxcyte has a P/B Ratio of 3.65. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Vaxcyte Stock (NASDAQ:PCVX)

Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against these emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.

PCVX Stock Price History

30 days | 90 days | 365 days | Advanced Chart

PCVX Stock News Headlines

November 30, 2023 | americanbankingnews.com

Vaxcyte, Inc. (NASDAQ:PCVX) CEO Sells $736,350.00 in Stock

November 25, 2023 | americanbankingnews.com

Insider Selling: Vaxcyte, Inc. (NASDAQ:PCVX) CFO Sells $409,040.00 in Stock

December 2, 2023 | DTI Trader (Ad)

New CBOE “special perk” helps traders target income every weekend

You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.

November 25, 2023 | americanbankingnews.com

Vaxcyte, Inc. (NASDAQ:PCVX) Receives Consensus Rating of "Buy" from Brokerages

November 23, 2023 | finance.yahoo.com

Insider Sell Alert: Vaxcyte Inc's President and CFO Andrew Guggenhime Sells 8,000 Shares

November 19, 2023 | ca.finance.yahoo.com

PCVX Jan 2024 45.000 put

November 9, 2023 | finance.yahoo.com

Vaxcyte Doses First Participants in Phase 1/2 Clinical Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in Adults

November 8, 2023 | msn.com

Vaxcyte GAAP EPS of -$0.91

December 2, 2023 | DTI Trader (Ad)

New CBOE “special perk” helps traders target income every weekend

You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.

November 7, 2023 | markets.businessinsider.com

Vaxcyte’s Promising Future: Successful Q3 Results, Favorable Clinical Progress, and Strong Financial Position Drive Boris Peaker’s Buy Rating

November 7, 2023 | finanznachrichten.de

Vaxcyte, Inc.: Vaxcyte Reports Third Quarter 2023 Financial Results and Provides Business Update

November 6, 2023 | finance.yahoo.com

Vaxcyte Reports Third Quarter 2023 Financial Results and Provides Business Update

November 6, 2023 | finance.yahoo.com

Vaxcyte Inc (PCVX) Reports Q3 2023 Financial Results and Business Updates

November 4, 2023 | finance.yahoo.com

Insider Sell: COO Jim Wassil Sells 3,000 Shares of Vaxcyte Inc (PCVX)

October 21, 2023 | finance.yahoo.com

Insider Sell: Andrew Guggenhime Sells 8,000 Shares of Vaxcyte Inc (PCVX)

October 19, 2023 | markets.businessinsider.com

Vaxcyte Says FDA OK's IND Application Of VAX-31 For Prevention Of Invasive Pneumococcal Disease

October 19, 2023 | finance.yahoo.com

Vaxcyte Announces FDA Clearance of Investigational New Drug Application for VAX-31 for the Prevention of Invasive Pneumococcal Disease in Adults

October 17, 2023 | markets.businessinsider.com

Vaxcyte’s Efficacy, Strategic Partnerships and Potential Dominance in Vaccine Industry: A Buy Rating Endorsement by Analyst Thomas Shrader

October 16, 2023 | markets.businessinsider.com

Vaxcyte’s Positive Outlook: Buy Rating Justified by Strategic Lonza Partnership and Promising Vaccine Candidates

October 16, 2023 | seekingalpha.com

Vaxcyte: End Of Phase 2 Meeting FDA Q4 Of 2023 To Get Ball Rolling

October 16, 2023 | finance.yahoo.com

Vaxcyte and Lonza Expand Collaboration for Global Commercial Manufacturing of Broad-Spectrum Pneumococcal Conjugate Vaccines (PCVs)

October 16, 2023 | msn.com

Vaxcyte teams up with Lonza to make pneumococcal conjugate vaccines

October 5, 2023 | finance.yahoo.com

Insider Sell: Vaxcyte Inc's COO Jim Wassil Sells 3,000 Shares

September 19, 2023 | finance.yahoo.com

Vaxcyte to Present at the 2023 Cantor Fitzgerald Global Healthcare Conference

August 22, 2023 | msn.com

Cantor Fitzgerald Reiterates Vaxcyte (PCVX) Overweight Recommendation

August 17, 2023 | msn.com

Strong Financials And Pipeline Position Vaxcyte For Success

August 9, 2023 | msn.com

Needham Reiterates Vaxcyte (PCVX) Buy Recommendation

See More Headlines

Receive PCVX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vaxcyte and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/06/2023
Today: 12/02/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 2/26/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:PCVX
CUSIP: N/A
CIK: 1649094
Web: www.vaxcyte.com
Phone: 650-837-0111
Fax: N/A
Employees: 158
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $64.20
High Stock Price Target: $70.00
Low Stock Price Target: $58.00
Potential Upside/Downside: +19.3%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 5 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($3.34)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-223,490,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -23.36%
Return on Assets: -22.06%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 15.14
Quick Ratio: 15.14

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $14.74 per share
Price / Book: 3.65

Miscellaneous

Outstanding Shares: 95,150,000
Free Float: 91,728,000
Market Cap: $5.12 billion
Optionable: Not Optionable
Beta: 0.88

Beginner's Guide to Pot Stock Investing

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

Mr. Grant E. Pickering M.B.A. (Age 55)
Co-Founder, CEO & Director
Comp: $1.1M
Mr. Andrew L. Guggenhime M.B.A. (Age 55)
President & CFO
Comp: $839.65k
Mr. James Wassil M.B.A. (Age 54)
M.S., Executive VP & COO
Comp: $826.3k
Mr. Mikhail Eydelman J.D. (Age 42)
Senior VP, General Counsel, Chief Compliance Officer & Corporate Secretary
Comp: $793.22k
Mr. Paul W. Sauer M.B.A. (Age 62)
Senior Vice President of Process Development & Manufacturing
Comp: $608.96k
Dr. Ashish Khanna M.B.A. (Age 51)
Ph.D., Co-Founder
Dr. Jeff Fairman Ph.D. (Age 59)
Co-Founder & VP of Research
Ms. Elvia Cowan (Age 50)
Senior VP of Finance & Principal Accounting Officer
Ms. Janet Graesser
Vice President of Corporate Communications & Investor Relations
Karen Alderete
Executive Director of Human Resources

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

PCVX Stock Analysis - Frequently Asked Questions

Should I buy or sell Vaxcyte stock right now?: 5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Vaxcyte in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" PCVX shares.
View PCVX analyst ratings or view top-rated stocks.
What is Vaxcyte's stock price target for 2024?: 5 equities research analysts have issued 12 month price targets for Vaxcyte's stock. Their PCVX share price targets range from $58.00 to $70.00. On average, they anticipate the company's share price to reach $64.20 in the next twelve months. This suggests a possible upside of 19.3% from the stock's current price.
View analysts price targets for PCVX or view top-rated stocks among Wall Street analysts.
How have PCVX shares performed in 2023?: Vaxcyte's stock was trading at $47.95 on January 1st, 2023. Since then, PCVX stock has increased by 12.2% and is now trading at $53.81.
View the best growth stocks for 2023 here.
When is Vaxcyte's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, February 26th 2024.
View our PCVX earnings forecast.
How were Vaxcyte's earnings last quarter?: Vaxcyte, Inc. (NASDAQ:PCVX) issued its earnings results on Monday, November, 6th. The company reported ($0.91) EPS for the quarter, missing the consensus estimate of ($0.84) by $0.07.
What ETFs hold Vaxcyte's stock?: ETFs with the largest weight of Vaxcyte (NASDAQ:PCVX) stock in their portfolio include ETFMG Treatments Testing and Advancements ETF (GERM), ALPS Medical Breakthroughs ETF (SBIO), Alger 35 ETF (ATFV), Alger Mid Cap 40 ETF (FRTY), Invesco Dorsey Wright Healthcare Momentum ETF (PTH), SPDR S&P Biotech ETF (XBI), Principal Healthcare Innovators ETF (BTEC) and Fidelity Disruptive Medicine ETF (FMED).

What other stocks do shareholders of Vaxcyte own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Vaxcyte investors own include NVIDIA (NVDA), Twilio (TWLO), Boeing (BA), Overstock.com (OSTK), Pure Storage (PSTG), QUALCOMM (QCOM), Riot Platforms (RIOT), American Tower (AMT), Avid Technology (AVID) and CalAmp (CAMP).
When did Vaxcyte IPO?: (PCVX) raised $210 million in an initial public offering (IPO) on Friday, June 12th 2020. The company issued 14,000,000 shares at a price of $14.00-$16.00 per share. BofA Securities, Jefferies and Evercore ISI acted as the underwriters for the IPO and Cantor and Needham & Company were co-managers.
Who are Vaxcyte's major shareholders?: Vaxcyte's stock is owned by many different retail and institutional investors. Top institutional investors include FMR LLC (14.79%), Wellington Management Group LLP (4.83%), Fred Alger Management LLC (2.20%), Jennison Associates LLC (1.87%), Braidwell LP (1.70%) and Kynam Capital Management LP (1.37%). Insiders that own company stock include Andrew Guggenhime, Grant Pickering, Group Holdings (Sbs) Advis Tpg, Heath Lukatch, Jane Wright-Mitchell, Jeff Fairman, Jim Wassil, Mikhail Eydelman, Paul Sauer and Robert Lorne Hopfner.
View institutional ownership trends.
How do I buy shares of Vaxcyte?: Shares of PCVX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:PCVX) was last updated on 12/2/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial